Widely used:Recently Viewed
Clear All
$621 Mln
--
2.56
--
0
-51.49 %
--
0 %
4.64
-2202642
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Stoke Therapeutics (STOK)
| 123.38 | -21.82 | -7.26 | 228.21 | -23.49 | -11.68 | -- |
|
BSE Sensex*
| 12.20 | -0.16 | 1.32 | 22.81 | 11.05 | 16.56 | 11.80 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|
|
Stoke Therapeutics (STOK)
| -43.01 | -61.53 | -61.26 | 118.68 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$620.72 Mln
$15.16 Mln
$-24.54 Mln
$282.06 Mln
$5.83 Mln
High
$3.35 - 17.58
52,647,800
NASDAQ: STOK
Bedford, MA
https://www.stoketherapeutics.com
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output... to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Read more
The total asset value of Stoke Therapeutics Inc (STOK) stood at $ 352 Mln as on 30-Jun-24
The share price of Stoke Therapeutics Inc (STOK) is $11.75 (NASDAQ) as of 04-Oct-2024 16:00 EDT. Stoke Therapeutics Inc (STOK) has given a return of -23.49% in the last 3 years.
Stoke Therapeutics Inc (STOK) has a market capitalisation of $ 621 Mln as on 04-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Stoke Therapeutics Inc (STOK) is 2.56 times as on 04-Oct-2024, a 18% discount to its peers’ median range of 3.12 times.
Since, TTM earnings of Stoke Therapeutics Inc (STOK) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Stoke Therapeutics Inc (STOK) and enter the required number of quantities and click on buy to purchase the shares of Stoke Therapeutics Inc (STOK).
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
The CEO & director of Dr. Edward M. Kaye M.D., Ph.D.. is Stoke Therapeutics Inc (STOK), and CFO & Sr. VP is Dr. Edward M. Kaye M.D., Ph.D..
There is no promoter pledging in Stoke Therapeutics Inc (STOK).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Stoke Therapeutics Inc. (STOK) | Ratios |
|---|---|
|
Return on equity(%)
|
-51.49
|
|
Operating margin(%)
|
-763.57
|
|
Net Margin(%)
|
-683.31
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Stoke Therapeutics Inc (STOK) was $-25 Mln.
$-0.06
